Nectin Therapeutics

Nectin Therapeutics Overview

Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies. The company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers. The company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.

Cumulative Funding Raised Over Time ($)

Latest News

May 6, 2024 · en.globes.co.il

growth-positive

Israeli biotech co Nectin Therapeutics raises $10m

Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Israeli biotechnology company Nectin Therapeutics. Nectin is developing targeted immunotherapies for resistance to approved immune oncology treatments. The investment will be used to continue the development of Nectins portfolio of novel immuno-oncology products, including the advancement of Nectins ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio.

Investment

May 16, 2023 · www.businesswire.com

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Feb 7, 2023 · www.biospace.com

growth-positive

Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace

Nectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of its novel anti-PVR antibody, NTX1088, in combination with Mercks anti-PD1 therapy, KEYTRUDA, in patients with solid tumors. NTX1088 aims to restore the antitumor immune activity of DNAM1 by blocking PVR, a protein associated with resistance to immune checkpoint inhibitors. The phase 1 trial with NTX1088 has already been initiated. The collaboration represents a promising new therapy for cancer patients and a milestone for Nectin Therapeutics.

Partners

Dec 1, 2022 · en.globes.co.il

growth-positive

Israeli co Nectin Therapeutics raises $25m

Nectin Therapeutics, an Israeli biotechnology company, has completed a $25 million Series A financing round led by IBF and Peregrine Ventures. The funding will be used to support the ongoing clinical evaluation of NTX1088, the companys first-in-class PVR (CD155) blocker, and to further advance its pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company has also announced the dosing of the first patient in its Phase I clinical trial of NTX1088, which is being conducted at The University of Texas MD Anderson Cancer Center. Nectin aims to overcome the limitations of existing IO therapies and provide new treatment options for patients with difficult-to-treat cancers.

InvestmentExpand

Nov 30, 2022 · www.prnewswire.com

growth-positive

Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors

Nectin Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial of NTX1088, a first-in-class PVR (CD155) blocker for cancer patients with advanced solid tumors. The trial is being conducted at MD Anderson Cancer Center with an investment from the Cancer Focus Fund. Nectin has also extended its Series A financing to over $25 million, with IBF and Peregrine Ventures leading the round. The funding will be used to support the ongoing clinical evaluation of NTX1088 and advance the companys pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). NTX1088 aims to restore DNAM-1 expression on immune cells and stimulate an anti-tumor immune response. PVR is overexpressed in many solid tumors and is associated with resistance to PD-1 and PD-L1 blockade. The Phase 1 trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.

InvestmentExpand

Funding

Team Members

5

Employees: 11-50

Web & Social Links

Locations

Givat Ram, Jerusalem, Israel

1 Bridge Plaza North, Fort Lee, NJ, USA

Photos & Videos

1 item(s)

Nectin Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info